Arena Pharmaceuticals Stock News

Pfizer stock rose near its 50-day line Friday after the drug giant wrapped its $6.7 billion takeover of biotech Arena Pharmaceuticals.

Source: [[https://pixabay.com/photos/laboratory-apparatus-equipment-217041/ Pixabay]] Pfizer announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Read more… |

Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis. It has said it expects to share data from a Phase 3 clinical trial testing one of those experimental therapies, etrasimod, in ulcerative colitis patients during the first quarter of his year. Pfizer''s stock has gained 45.0% over the past year, while the broader S&P 500 is up 10.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Shares of Pfizer Inc. PFE, +2.32% were up 2.0% in trading on Friday after the company said it closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing treatments for immun

Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA) is now expected…

Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest

Arena Pharmaceuticals (ARNA) rose 1.1% in after hours trading after a Nasdaq delisting notice indicated the company''s last trading day would be Thursday due to the completion of its sale…

Futures Rebound On "Massive" EU Bond Stimulus Plan; Nickel Halted After Record Surge, Gold Over $2000 Futures rebounded from yesterday huge loss, and after touching a session low of 4,138, S&P futures bounced shortly after the European when Bloomberg reported that the European Union was set to reveal a quasi "Marshall Plan" this week to issue issue "potentially massive” joint bonds to fund energy and defense and help counter the fiscal fallout from Russia’s invasion of Ukraine (how Europe will do that at a time when QE is ending and buyers for global debt are shrinking fast amid surging rates remains unclear). S&P 500 futures gained 0.7% following the benchmark index’s biggest loss since October 2020, while Dow futures rose 0.6%. Contracts on the Nasdaq 100 were up 0.6% at 7:15 a.m. Bonds and the dollar dropped, and the euro strengthened. The commodity melt up continued: nickel was halted on the LME after soaring 250%, oil traded just shy of $130 and gold was above $2000. The EU''s bond-sale proposal may be presented as soon as next week, according to Bloomberg.

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we mak

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revealed Wednesd…

Arena Pharmaceuticals press release (ARNA): Q4 GAAP EPS of -$2.54 misses by $0.31.Cash, cash equivalents and marketable securities were $0.7B at December 31, 2021 as compared to $1.1B…

PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ARNA--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021